Statins in the Treatment of Polycystic Ovary Syndrome

Kodaman, Pinar H.; Dulęba, Antoni J.

doi:10.1055/s-2007-992933

Cited by 36 publications

(33 citation statements)

References 166 publications

(164 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been shown that several circulating markers of oxidative stress are abnormal in women with PCOS, independent of weight excess (187). Oxidative stress in PCOS may participate in systemic inflammation and together with insulin resistance and consequent hyperinsulinaemia promote ovarian thecal compartment dysregulation and dysfunction of endothelial cells, resulting in hyperandrogenism, anovulation and CV disorders (188).…”

Section: Role Of Lipo-oxidative Stressmentioning

confidence: 99%

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

Conway¹,

Dewailly²,

Diamanti-Kandarakis³

et al. 2014

European Journal of Endocrinology

576

492

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common ovarian disorder associated with androgen excess in women, which justifies the growing interest of endocrinologists. Great efforts have been made in the last 2 decades to define the syndrome. The presence of three different definitions for the diagnosis of PCOS reflects the phenotypic heterogeneity of the syndrome. Major criteria are required for the diagnosis, which in turn identifies different phenotypes according to the combination of different criteria. In addition, the relevant impact of metabolic issues, specifically insulin resistance and obesity, on the pathogenesis of PCOS, and the susceptibility to develop earlier than expected glucose intolerance states, including type 2 diabetes, has supported the notion that these aspects should be considered when defining the PCOS phenotype and planning potential therapeutic strategies in an affected subject. This paper offers a critical endocrine and European perspective on the debate on the definition of PCOS and summarises all major aspects related to aetiological factors, including early life events, potentially involved in the development of the disorder. Diagnostic tools of PCOS are also discussed, with emphasis on the laboratory evaluation of androgens and other potential biomarkers of ovarian and metabolic dysfunctions. We have also paid specific attention to the role of obesity, sleep disorders and neuropsychological aspects of PCOS and on the relevant pathogenetic aspects of cardiovascular risk factors. In addition, we have discussed how to target treatment choices based according to the phenotype and individual patient's needs. Finally, we have suggested potential areas of translational and clinical research for the future with specific emphasis on hormonal and metabolic aspects of PCOS.

show abstract

Section: Role Of Lipo-oxidative Stressmentioning

confidence: 99%

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

Conway¹,

Dewailly²,

Diamanti-Kandarakis³

et al. 2014

European Journal of Endocrinology

576

492

View full text Add to dashboard Cite

show abstract

“…[Diamanti-Kandarakis et al 2008;Kodaman and Duleba, 2008a] The insulin resistance and hyperinsulinaemia pathophysiologically implicated in the metabolic and reproductive abnormalities of PCOS [De Leo et al 2003;Nestler, 1997] are the two major facets of the metabolic syndrome (MS) [Reaven, 1988]. MS is characterized by a cluster of metabolic disturbances, such as central obesity, impaired glucose tolerance, dyslipidemia and hypertension that are related to increased cardiovascular risk [Schneider et al 2006].…”

Section: The Effects Of Old New and Emerging Medicines On Metabolic mentioning

confidence: 99%

“…They also express anti-oxidant, antiflammatory and antiprolifarative effects [Kodaman and Duleba, 2008a;Wassmann et al 2002] and together with the lipid reduction these alterations can have a beneficial effect on the long-term cardiovascular morbidity and mortality associated with PCOS ( Figure 2). …”

Section: Statinsmentioning

confidence: 99%

The effects of old, new and emerging medicines on metabolic aberrations in PCOS

Bargiota¹,

Diamanti-Kandarakis²

2012

Therapeutic Advances in Endocrinology

100

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age that is associated with significant adverse short-and long-term health consequences. Multiple metabolic aberrations, such as insulin resistance (IR) and hyperinsulinaemia, high incidence of impaired glucose tolerance, visceral obesity, inflammation and endothelial dysfunction, hypertension and dyslipidemia are associated with the syndrome. Assessing the metabolic aberrations and their long term health impact in women with PCOS is challenging and becomes more important as therapeutic interventions currently available for the management of PCOS are not fully able to deal with all these consequences. Current therapeutic management of PCOS has incorporated new treatments resulting from the better understanding of the pathophysiology of the syndrome. The aim of this review is to summarize the effect of old, new and emerging therapies used in the management of PCOS, on the metabolic aberrations of PCOS

show abstract

“…However, it is difficult at present to understand whether the oxidative stress or hyperandrogenemia is the initiating factor. Oxidative stress is accepted as the triggering factor for thecal androgen production in PCOS [23]. But the effect of androgens on the pathogenesis of atherosclerosis in different sexes is controversial [24].…”

Section: Cardiovascular Risks Have Been Shown To Be Increased Among Pmentioning

confidence: 99%

Paraoxonase-1 is not affected in polycystic ovary syndrome without metabolic syndrome and insulin resistance, but oxidative stress is altered

Torun

Vural

Çeçe

et al. 2011

Gynecological Endocrinology

View full text Add to dashboard Cite

Paraoxonase-1 (PON1) activity is decreased in polycystic ovary syndrome (PCOS) having metabolic syndrome (MetS) or insulin resistance (IR). We aimed to assess PON1 activity and oxidative stress in PCOS without MetS or IR. Metabolic and hormonal parameters, high-sensitive C-reactive protein (hs-CRP), oxidative stress parameters (total antioxidant status (TAS), total oxidative stress (TOS), oxidative stress index (OSI), lipid hydroperoxide (LOOH), total free sulfhydryl (--SH) groups), PON and arylesterase were analyzed in 30 normal weighed patients with PCOS without MetS or IR and 20 normal controls. Hs-CRP, PON, arylesterase, and TAS levels of PCOS and control groups were similar. LOOH, TOS, and OSI of PCOS group were higher than in the controls (p < 0.05; p < 0.001, and p < 0.001, respectively). - SH group levels showed a positive correlation with free testosterone (fT). TOS positively correlated with free androgen index (FAI), body mass index (BMI), waist-to-hip ratio (WHR), LOOH, and OSI. This study showed that oxidative stress is increased in PCOS even in the absence of MetS or IR. PON1 activity appears not to be affected in PCOS without MetS and IR. Several metabolic and antropometric risk factors may aggravate this altered oxidative state in PCOS.

show abstract

Statins in the Treatment of Polycystic Ovary Syndrome

Cited by 36 publications

References 166 publications

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

The effects of old, new and emerging medicines on metabolic aberrations in PCOS

Paraoxonase-1 is not affected in polycystic ovary syndrome without metabolic syndrome and insulin resistance, but oxidative stress is altered

Contact Info

Product

Resources

About